Abstract
We have previously shown that peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists inhibited the inflammatory response of RSV-infected human lung epithelial cells. In this study, we supply evidence that specific PPARgamma agonists (15d-PGJ2, ciglitazone, troglitazone, Fmoc-Leu) efficiently blocked the RSV-induced cytotoxicity and development of syncytia in tissue culture (A549, HEp-2). All PPARgamma agonists under study markedly inhibited the cell surface expression of the viral G and F protein on RSV-infected A549 cells. This was paralleled by a reduced cellular amount of N protein-encoding mRNA determined by real-time RT-PCR. Concomitantly, a reduced release of infectious progeny virus into the cell supernatants of human lung epithelial cells (A549, normal human bronchial epithelial cells (NHBE)) was observed. Similar results were obtained regardless whether PPARgamma agonists were added prior to RSV infection or thereafter, suggesting that the agonists inhibited viral gene expression and not the primary adhesion or fusion process.
References
Nov 1, 1994·Archives of Disease in Childhood·M L EverardA D Milner
Jan 25, 2000·The Journal of Biological Chemistry·A BonazziM Laniado-Schwartzman
Feb 5, 2000·JAMA : the Journal of the American Medical Association·W P GlezenR B Couch
Aug 11, 2000·Paediatric Drugs·N N Dougherty, H C Meissner
Nov 15, 2000·The Journal of Infectious Diseases·D K ShayL J Anderson
Jun 21, 2001·American Journal of Respiratory Cell and Molecular Biology·A C WangD J Conrad
Oct 31, 2001·Molecular Cell·S RocchiJ Auwerx
Apr 20, 2002·Current Opinion in Infectious Diseases·J L Kimpen
Jun 22, 2002·The Journal of Biological Chemistry·Rafal PawliczakTong Wu
Oct 3, 2002·Nature Reviews. Immunology·Raymond A Daynes, Dallas C Jones
May 15, 2003·Endocrinology·Chih-Hao LeeRonald M Evans
Jul 30, 2003·Journal of Virology·Birgit BossertKarl-Klaus Conzelmann
Sep 17, 2003·The Journal of Clinical Investigation·L Chastine Bell-ParikhGarret A FitzGerald
Jan 27, 2004·Antimicrobial Agents and Chemotherapy·Christopher CianciMark Krystal
Feb 13, 2004·FEBS Letters·Xiaoyuan KongShyam S Mohapatra
Mar 30, 2004·Journal of Virology·Kirsten M SpannPeter L Collins
Apr 21, 2004·BioFactors·Eiko ImamotoToshikazu Yoshikawa
Jul 6, 2004·Journal of Virological Methods·G Dewhurst-MaridorJ C Pache
Nov 30, 2004·Virology·Ralf ArnoldWolfgang König
Dec 28, 2004·Nature Medicine·Vira BitkoSailen Barik
Jan 5, 2005·Virology·Kerstin ReimersHermann Werchau
Mar 16, 2005·Journal of Virology·Xiaodong Zhao, Wayne M Sullender
May 27, 2005·Antimicrobial Agents and Chemotherapy·Janet L DouglasTomas Cihlar
Dec 7, 2005·Virology·Ralf Arnold, Wolfgang König
Citations
Aug 18, 2010·Viral Immunology·Josep Bassaganya-RieraRaquel Hontecillas
Feb 6, 2013·Medical Molecular Morphology·Jun FuchimotoNorimasa Sawada
May 1, 2010·Biochemical and Biophysical Research Communications·Yuta WakuiTooru Shimosegawa
Apr 12, 2007·Immunology·Ralf ArnoldWolfgang König
Oct 3, 2014·The Journal of General Virology·Lili XuChuan Qin
Feb 27, 2014·BMB Reports·Tae Hoon Kim, Heung Kyu Lee
Jun 28, 2008·PPAR Research·Catherine GurleyTammy Kielian
Aug 13, 2013·PloS One·Manuel MataJulio Cortijo
May 8, 2016·Antiviral Research·Lei QiaoZishu Pan
Dec 21, 2011·Antiviral Chemistry & Chemotherapy·Pilar NajarroKenneth Powell
Jan 19, 2020·Viruses·Hi Eun JungHeung Kyu Lee
Mar 20, 2018·Frontiers in Immunology·Stephanie AscoughChristopher Chiu
Aug 18, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Merilin Al Sharif
May 11, 2018·Science Translational Medicine·Rhiannon B WerderSimon Phipps